Mar 26 2010
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that
the U.S. Food and Drug Administration (FDA) has granted tentative
approval for the Company's Abbreviated New Drug Application (ANDA) to
market a generic version of the anticoagulant, Argatroban® injection,
100mg/mL.
The brand product had annual sales of approximately $137 million in the
United States, based on IMS sales data. On Feb. 12, 2010, a bench trial
in an ongoing patent litigation was completed in the U.S. District Court
for the Southern District of New York.
Source:
Teva Pharmaceutical Industries Ltd.,
Healthy lifestyle choices can offset genetic risk for brain diseases